Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.

Gasser UE, Fischer A, Timmermans JP, Arnet I.

BMC Pharmacol Toxicol. 2013 Apr 23;14:24. doi: 10.1186/2050-6511-14-24.

2.

Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

Keller GA, Czerniuk P, Bertuola R, Spatz JG, Assefi AR, Di Girolamo G.

Clin Ther. 2011 Apr;33(4):500-10. doi: 10.1016/j.clinthera.2011.04.012.

PMID:
21635995
3.

Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).

Taylor PW, Arnet I, Fischer A, Simpson IN.

Obes Facts. 2010 Aug;3(4):231-7. doi: 10.1159/000319450. Epub 2010 Aug 9.

4.

Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.

Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.

Eur Neurol. 1987;27 Suppl 1:54-8.

PMID:
3322837
5.

Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.

Crevoisier C, Hoevels B, Zürcher G, Da Prada M.

Eur Neurol. 1987;27 Suppl 1:36-46.

PMID:
3428308
6.

Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?

Smith JC, Tarocco G, Merazzi F, Salzmann U.

Curr Med Res Opin. 2006 Apr;22(4):709-20.

PMID:
16684432
7.

[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].

Dessibourg CA, Gachoud JP.

Praxis (Bern 1994). 1995 Oct 24;84(43):1235-8. German.

PMID:
7481341
9.

Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane.

Taylor PW, Keenan MH.

Curr Med Res Opin. 2006 Mar;22(3):603-15.

PMID:
16574043
11.

A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.

Graham JS, Henderson JM, Morris JG, Yiannikas C.

Aust N Z J Med. 1991 Feb;21(1):11-5.

PMID:
2036070
12.

Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.

Grahnén A, Eckernäs SA, Collin C, Ling-Andersson A, Tiger G, Nilsson M.

Eur Neurol. 1992;32(6):343-8.

PMID:
1490503
14.
15.

Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.

Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE.

J Neurol Neurosurg Psychiatry. 1981 Dec;44(12):1116-23.

16.
17.
18.

Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.

Pacchetti C, Martignoni E, Sibilla L, Bruggi P, Turla M, Nappi G.

Eur Neurol. 1990;30(6):319-23.

PMID:
2289507
19.

Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.

Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.

Eur Neurol. 1987;27 Suppl 1:88-92.

PMID:
3322841
20.

Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.

Nordera GP, Lorizio A, Lion P, Durisotti C, D'Andrea G, Ferro-Milone F.

Eur Neurol. 1987;27 Suppl 1:76-80.

PMID:
3322839

Supplemental Content

Support Center